Literature DB >> 31260111

Chronic liver involvement in urea cycle disorders.

Giusy Ranucci1, Miriam Rigoldi2, Giovanna Cotugno1, Silvia Maria Bernabei3, Alessandra Liguori1, Serena Gasperini4, Bianca Maria Goffredo1, Diego Martinelli1, Lidia Monti5, Paola Francalanci6, Manila Candusso7, Rossella Parini4, Carlo Dionisi-Vici1.   

Abstract

The increased survival of urea cycle disorders (UCDs) patients has led the attention to clinical manifestations that characterize the long-term disease course. Acute and chronic liver disease have been anecdotally reported since the very first description of UCDs. However, a detailed analysis of long-term liver involvement in large patient cohorts is still needed. Chronic liver damage in UCDs has probably a multifactorial origin, but the specific underlying mechanisms of liver disease have not yet been well elucidated. In this study, we report on chronic liver involvement and on associated metabolic abnormalities in a large cohort of 102 UCD patients, followed by two reference centers in Italy. Chronic liver involvement was observed in over 60% of UCDs patients, and comparison between individual diseases showed a significant higher frequency in argininosuccinate lyase deficiency (ASLD) and in hyperornithinemia-hyperammonemia-homocitrullinemia (HHH) syndrome with elevation of transaminases and of gamma-GT in ASLD, and of alpha-fetoprotein in HHH syndrome. Also, consistent with a chronic hepatic dysfunction, ultrasound examination revealed more pronounced abnormalities in ASLD and in HHH syndrome, when compared to other UCDs. Our study highlights in a large UCDs patients' cohort that chronic liver disease is a common finding in UCDs, often with a distinct phenotype between different diseases. Furthers studies are needed to elucidate the specific involvement of different metabolic pathways in the pathogenesis of liver dysfunction in UCDs.
© 2019 SSIEM.

Entities:  

Keywords:  argininosuccinate lyase deficiency; chronic liver disease; hyperornithinemia-hyperammonemia-homocitrullinemia syndrome; incomplete septal cirrhosis; lean nonalcoholic fatty liver disease; metabolic syndrome; urea cycle disorders

Year:  2019        PMID: 31260111     DOI: 10.1002/jimd.12144

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  5 in total

1.  Chronic liver disease and impaired hepatic glycogen metabolism in argininosuccinate lyase deficiency.

Authors:  Lindsay C Burrage; Simran Madan; Xiaohui Li; Saima Ali; Mahmoud Mohammad; Bridget M Stroup; Ming-Ming Jiang; Racel Cela; Terry Bertin; Zixue Jin; Jian Dai; Danielle Guffey; Milton Finegold; Sandesh Nagamani; Charles G Minard; Juan Marini; Prakash Masand; Deborah Schady; Benjamin L Shneider; Daniel H Leung; Deeksha Bali; Brendan Lee
Journal:  JCI Insight       Date:  2020-02-27

2.  Biomarkers for liver disease in urea cycle disorders.

Authors:  Sandesh C S Nagamani; Saima Ali; Rima Izem; Deborah Schady; Prakash Masand; Benjamin L Shneider; Daniel H Leung; Lindsay C Burrage
Journal:  Mol Genet Metab       Date:  2021-04-08       Impact factor: 4.204

3.  Severe Protein-Calorie Malnutrition-Associated Hepatic Steatosis in a Woman Who Had Roux-en-Y Gastric Bypass for Morbid Obesity Thirteen Years Ago.

Authors:  Guriel N Kim; Sam Ho; David Saulino; Xiuli Liu
Journal:  Gastroenterology Res       Date:  2021-04-21

4.  Wilson's Disease and Hyperornithinemia-hyperammonemia-homocitrullinuria Syndrome in a Child: A Case Report with Lessons Learned!

Authors:  Meranthi Fernando; Suresh Vijay; Saikat Santra; Mary A Preece; Rachel Brown; Astor Rodrigues; Girish L Gupte
Journal:  Euroasian J Hepatogastroenterol       Date:  2021 Jul-Dec

5.  Beclin-1-mediated activation of autophagy improves proximal and distal urea cycle disorders.

Authors:  Leandro R Soria; Sonam Gurung; Giulia De Sabbata; Dany P Perocheau; Angela De Angelis; Gemma Bruno; Elena Polishchuk; Debora Paris; Paola Cuomo; Andrea Motta; Michael Orford; Youssef Khalil; Simon Eaton; Philippa B Mills; Simon N Waddington; Carmine Settembre; Andrés F Muro; Julien Baruteau; Nicola Brunetti-Pierri
Journal:  EMBO Mol Med       Date:  2020-12-28       Impact factor: 12.137

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.